VEGF

[Journal of Diabetes Research] Scientists prepared and identified endothelial progenitor cells (EPCs), and the biological functions and molecular characteristics were compared between EPCs from DB/+ and DB/DB mice.

[Experimental and Molecular Medicine] Researchers examined the functional role of regulated in development and DNA damage responses 1 (REDD1), an inhibitor of mammalian target of rapamycin complex 1, in low-dose metronomic chemotherapy-mediated endothelial cell dysfunction.

[Cell Death & Disease] Natriuretic peptide receptor A protected HIF-1α from proteolysis by binding to HIF-1α, increased the expression of HIF-1α, and promoted gastric cancer angiogenesis.

[BMC Cancer] The anti-cancer activities of BD0801 and its potential synergistic anti-tumor effects when combined with different immunotherapies were assessed by using in vitro assays and in vivo tumor models.

[Genentech] The US FDA approved Susvimo™ for intravitreal use via ocular implant for the treatment of people with wet, or neovascular, AMD who have previously responded to at least two anti-VEGF injections.

[Servier (Business Wire, Inc.)] Servier announced that the primary objective of the Phase III SOLSTICE trial has not been met. SOLSTICE was designed to evaluate the superiority of LONSURF® + bevacizumab over capecitabine + bevacizumab in first line unresectable metastatic colorectal cancer.